NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06582771 2026-02-05
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05118854 2025-10-20
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05631249 2025-05-08
CODEBREAK-IGR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT05398094 2025-04-10
MERIT-lung
Fundación GECP
Phase 2 Recruiting
NCT06068153 2024-11-20
AMBER
ETOP IBCSG Partners Foundation
Phase 2 Withdrawn
NCT05815186 2024-03-29
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
NYU Langone Health
Phase 2 Withdrawn
NCT05311709 2023-11-09
SOLUCOM
Vestre Viken Hospital Trust
Phase 2 Unknown
NCT05993455 2023-08-15
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Korea University Anam Hospital
Phase 2 Unknown
NCT05400577 2023-07-17
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT05451056 2022-07-11
breakthrough
Yonsei University
Phase 2 Unknown